Association of IL-4 and IL-1RN (receptor antagonist) gene variants and the risk of type 2 diabetes mellitus: A study in the north Indian population

Indian Journal of Medical Sciences

Volumn 62, Issue 7, 2008, Pages 259-266

  Bid, Hemant ^a   Konwar, Rituraj ^a   Agrawal, C ^a   Banerjee, Monisha ^a  

^a UNIVERSITY OF LUCKNOW   (India)

Author keywords

IL 1RN; IL 4; Polymorphism; Type 2 diabetes mellitus

Indexed keywords

GENOMIC DNA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 4;

ADULT; ARTICLE; BLOOD; CALCULATION; COMPARATIVE STUDY; COMPUTER PROGRAM; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA ISOLATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STATISTICAL ANALYSIS; TANDEM REPEAT; VARIABLE NUMBER OF TANDEM REPEAT;

ALLELES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDIA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-4; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 48249112526     PISSN: 00195359     EISSN: 19983654     Source Type: Journal    
DOI: 10.4103/0019-5359.42021     Document Type: Article

References (23)

1. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-92.
2. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23.
3. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Atherosclerosis Risk in Communities Study, Low-grade systemic inflammation and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 2003;52:1799-805.
4. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-independent diabetes mellitus. Biochem Pharmacol 1998;55:1139-49.
5. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003;52:812-7.
6. O'Connor JC, Sherry CL, Guest CB, Freund GG. Type 2 diabetes impairs insulin receptor substrate-2-mediated phosphatidylinositol 3-kinase activity in primary macrophages to induce a state of cytokine resistance to IL-4 in association with overexpression of suppressor of cytokine signaling-3. J Immunol 2007;178:6886-93.
7. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000;343:732-4.
8. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose-induced beta-cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851-60.
9. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-26.
10. Pfleger C, Mortensen HB, Hansen L, Herder C, Roep BO, Hoey H, et al. Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 2008;57:929-37.
11. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004;27:S11-4.
12. Dixit M, Bhattacharya S, Mittal B. Association of CETP TaqI and APOE polymorphisms with type II diabetes mellitus in North Indians: A case control study. BMC Endocr Disord 2005;1:5-7.
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1998;16:1215.
14. Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, Bid HK. Association of IL-4 and IL-1 Receptor Antagonist (IL-1Ra) gene polymorphisms and the risk of benign prostatic hyperplasia (BPH). Urology 2008;71:868-72.
15. Bid HK, Manchanda PK, Mittal RD. Association of interleukin-1Ra gene polymorphism in patients with bladder cancer: Case control study from North India. Urology 2006;67:1099-104.
16. Tsiavou A, Hatziagelaki E, Chaidaroglou A, Manginas A, Koniavitou K, Degiannis D, et al. TNF-alpha, TGF-beta1, IL-10, IL-6, gene polymorphisms in latent autoimmune diabetes of adults (LADA) and type 2 diabetes mellitus. J Clin Immunol 2004;24:591-9.
17. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51.
18. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665-8.
19. Hotamisligil GS. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-5.
20. Danielsson P, Truedsson L, Eriksson KF, Norgren L. Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vasc Med 2005;10:191-8.
21. Zeggini E, Groves CJ, Parkinson JR, Halford S, Owen KR, Frayling TM, et al. Large-scale studies of the association between variation at the TNF/LTA locus and susceptibility to type 2 diabetes. Diabetologia 2005;48:2013-7.
22. Maier LM, Chapman J, Howson JM, Clayton DG, Pask R, Strachan DP, et al. No evidence of association or interaction between the IL4RA, IL4, and IL13 genes in type 1 diabetes. Am J Hum Genet 2005;76:517-21.
23. Achyut BR, Srivastava A, Bhattacharya S, Mittal B. Genetic association of interleukin-1β (-511C-T) and interleukin-1 receptor antagonist (86 bp repeat) polymorphisms with Type 2 diabetes mellitus in North Indians. Clin Chim Acta 2007;377:163-9.